Cochrane · systematic review · CD010744
Smoking cessation for people with chronic obstructive pulmonary disease
van Eerd, EAM, van der Meer, RM, van Schayck, OCP, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 6 · 46.2%Very low 0 · 0%Low 1 · 7.7%Moderate 3 · 23.1%High 3 · 23.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Behavioural treatment compared to no treatment or usual care in smokers with COPD
Population: smokers with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Prolonged abstinence at longest Behavioural treatment vs no treatment or usual care | RR 25.38 [8.03, 80.22] | 1 study · 3562 participants | Moderate Downgraded: risk of bias |
Point prevalence abstinence at longest Behavioural treatment vs no treatment or usual care | no estimate extracted | 2 studies · 3618 participants | Ungraded |
One form of behavioural treatment compared to a different form of behavioural treatment in smokers with COPD
Population: smokers with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Prolonged abstinence at longest One form of behavioural treatment vs a different form of behavioural treatment | no estimate extracted | 4 studies · 739 participants | Ungraded |
Point prevalence abstinence at longest One form of behavioural treatment vs a different form of behavioural treatment | no estimate extracted | 3 studies · 500 participants | Ungraded |
Pharmacological treatment compared to placebo in smokers with COPD
Population: smokers with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Prolonged abstinence at longest Pharmacological treatment vs placebo | RR 2.53 [1.83, 3.5] | 4 studies · 1429 participants | High |
Prolonged abstinence at longest Pharmacological treatment vs placebo | RR 2.6 [1.29, 5.24] | 1 study · 370 participants | High |
Prolonged abstinence at longest Pharmacological treatment vs placebo | RR 2.03 [1.26, 3.28] | 2 studies · 503 participants | Moderate Downgraded: risk of bias, imprecision |
Prolonged abstinence at longest Pharmacological treatment vs placebo | RR 3.34 [1.88, 5.92] | 1 study · 504 participants | High |
Prolonged abstinence at longest Pharmacological treatment vs placebo | RR 2.54 [0.87, 7.44] | 1 study · 100 participants | Low Downgraded: risk of bias |
Pharmacological treatment compared to a different pharmacological treatment for smokers with COPD
Population: smokers with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Prolonged abstinence at longest Pharmacological treatment vs a different pharmacological treatment | no estimate extracted | 2 studies · 166 participants | Ungraded |
Point prevalence abstinence at longest Pharmacological treatment vs a different pharmacological treatment | RR 2.5 [1.47, 4.26] | 1 study · 543 participants | Moderate Downgraded: risk of bias |
Combination interventions compared to different (combination) interventions or usual care for smokers with COPD
Population: smokers with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Prolonged abstinence at longest Combination interventions vs different (combination) interventions or usual care | no estimate extracted | 4 studies · 6431 participants | Ungraded |
Point prevalence abstinence at longest Combination interventions vs different (combination) interventions or usual care | no estimate extracted | 4 studies · 1535 participants | Ungraded |